drugset / Trial / NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2022-06-30
- Primary completion
- 2024-01-29
- Completion
- 2024-01-29
Outcome
Outcome not reported
Stopped: “Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR20.19.22 | Cell therapy | 750000 cells/kg | Intravenous |
| Subject | CAR20.19.22 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CAR20.19.22 | Cell therapy | 2.5e+06 cells/kg | Intravenous |
| Subject | CAR20.19.22 | Cell therapy | 5e+06 cells/kg | Intravenous |